Bora Pharmaceuticals Co. posted a 94.88% year-over-year surge in March revenue to NT$14.7 billion (US$461 million), pushing its first-quarter sales to a record NT$48.3 billion (US$1.51 billion), up 69.04% from a year earlier.
Taiwan’s largest contract development and manufacturing organization cited robust performance in its CDMO business, which has already secured production orders for over 20 new molecular entities this year, compared to 40 throughout all of last year. The company expects to surpass 2024’s CDMO performance as manufacturing capacity investments in the US begin to pay off.
To strengthen its specialty pharmaceuticals portfolio, Bora signed an agreement with a neurological drug distributor to expand its epilepsy treatment Vigafyde, aiming to integrate its epilepsy-related products marketing and sales networks.
Despite slower month-over-month growth as the company shifts away from underperforming generic medications in the US market, management described the results as in line with expectations. Bora’s strategic pivot prioritizes higher-margin specialty pharmaceuticals while phasing out products facing intense price pressure.
The company, which operates ten manufacturing facilities globally and serves more than 100 markets, continues its transformation from a traditional pharmaceutical manufacturer to a globally-focused CDMO powerhouse.
